share_log

EFFECT: Others

EFFECT: Others

EFFECT:其他
美股SEC公告 ·  08/02 06:10
Moomoo AI 已提取核心信息
eFFECTOR Therapeutics, Inc. has achieved a significant milestone with the Securities and Exchange Commission (SEC) declaring its submission effective as of August 1, 2024. The company's filing, identified by accession number 0001193125-24-188836 and submission type POS AM, has been successfully processed, as indicated by the SEC's Notice of Effectiveness. This development is crucial for eFFECTOR Therapeutics as it pertains to the company's regulatory filings and potential future offerings.
eFFECTOR Therapeutics, Inc. has achieved a significant milestone with the Securities and Exchange Commission (SEC) declaring its submission effective as of August 1, 2024. The company's filing, identified by accession number 0001193125-24-188836 and submission type POS AM, has been successfully processed, as indicated by the SEC's Notice of Effectiveness. This development is crucial for eFFECTOR Therapeutics as it pertains to the company's regulatory filings and potential future offerings.
eFFECTOR Therapeutics, Inc.已在2024年8月1日获得证券交易委员会(SEC)的重要里程碑。该公司的申报文件编号为0001193125-24-188836,提交类型为pos am,已成功处理,如SEC的有效通知所示。对于eFFECTOR Therapeutics而言,这一进展对其监管申报和未来潜在的发行至关重要。
eFFECTOR Therapeutics, Inc.已在2024年8月1日获得证券交易委员会(SEC)的重要里程碑。该公司的申报文件编号为0001193125-24-188836,提交类型为pos am,已成功处理,如SEC的有效通知所示。对于eFFECTOR Therapeutics而言,这一进展对其监管申报和未来潜在的发行至关重要。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息